Labcorp — Apr 30, 2026 release

Revenue: $3.54 billion vs. $3.35 billion, up 5.8% ◦ Diluted EPS: $3.35 vs. $2.52, up 32.8% ◦ Adjusted EPS: $4.25 vs. $3.84, up 10.6% • Raised Full-Year Enterprise Revenue and Adjusted EPS guidance: ◦ Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpoint ◦ Adjusted EPS range of $17.70 to $18.35; up 13 cents at the midpoint • Advanced leadership in specialty and companion diagnostics and expanded strategic health systems collaborations • Collaborated with Optum.ai to enhance patient and provider experience BURLINGTON, N.C., April 30, 2026 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2026 and updated full-year guidance. “Labcorp delivered another quarter of strong results, with robust growth and double-digit Adjusted EPS growth driven by continued momentum across our Diagnostics and Central Laboratory businesses,” said Adam Schechter, Chairman and CEO of Labcorp. “Health systems, providers, consumers, and biopharmaceutical customers are increasingly turning to Labcorp as their partner of choice for their complex, innovative testing needs. Our investments in advanced technologies, including robotics and AI, are improving the customer experience and transforming the way we operate. Driven by continued progress across our strategic priorities, we are raising our full year Adjusted